Day: August 6, 2024

Talkspace 2Q 2024 Earnings Infographic Talkspace’s Second Quarter 2024 Earnings Results 2Q 2024 Total revenue grew 29% year-over-year, driven by 62%year-over-year growth in Payor revenue Reduced GAAP Net loss to $0.5 million from $4.7 million year-over-year 2Q 2024 Adjusted EBITDA1 of $1.2 million Board approved an additional $25 million share repurchase program NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) — Talkspace, Inc. (“Talkspace” or the “Company”) (NASDAQ: TALK), today reported second quarter 2024 financial results.     Three Months   Six Months       June 30, 2024 (Unaudited)   Results   % Variance from Prior Year   Results   % Variance from Prior Year (In thousands unless otherwise noted)                 Number of eligible lives at period end (in millions)     145.3     33 %     145.3     33 % Number...

Clinical update presented at ASCO 2024 for CRB-701 showed continued differentiated safety and encouraging efficacy in patients with metastatic urothelial cancer or cervical cancer CRB-701 Phase 1 dose escalation underway in USA and Europe for patients with metastatic urothelial cancer and other nectin-4 enriched tumors and is on schedule for completion in Q4 2024 Cash runway extended through Q3 2027 with $147 million of cash & investments at June 30, 2024 NORWOOD, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today provided a corporate update and reported financial results for the quarter ended June 30, 2024. “We continue to make progress across our pipeline,” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. “Updated clinical data was...

  Second quarter net sales of $140.8 million down 4.9% year over year (organic1 down 3.4%); net sales up 13.3% sequentially over the first quarter. Gross profit of $30.5 million down 5.4% year over year; gross margins were flat at 21.7%. Second quarter net income of $2.8 million down $0.7 million, or 19.4%, from the prior year; second quarter adjusted EBITDA1 of $8.1 million down $2.5 million, or 23.8%, from the prior year. Net debt1 of $83.2 million down $2.5 million from the prior year quarter end and Gross Leverage Ratio1 of 2.7x up 0.2x over last year’s comparable quarter end. Second quarter new orders1 were $171.0 million, down $12.7 million from last year, but up sequentially $38.6 million, or 29.2%. The trailing twelve month book-to-bill ratio1 was 0.93 : 1.00. Backlog1 was $249.8 million, down $40.3 million from last year’s...

SUMMIT, PEAK and APEX registration-directed clinical trial enrollment remains on track; topline results expected from all three studies in 2025 Ended 2Q 2024 with $390 million, sufficient to fund operations into 2027 WALTHAM, Mass. and BOULDER, Colo., Aug. 06, 2024 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today reported financial results for the second quarter ended June 30, 2024. “Cogent has made tremendous progress in the first half of 2024 and we look forward to continuing to execute on our key priorities across the portfolio,” said Andrew Robbins, the Company’s President and Chief Executive Officer. “All three of our bezuclastinib registration-directed trials remain on track and we expect to complete enrollment...

CHICAGO, Aug. 06, 2024 (GLOBE NEWSWIRE) — Portillo’s Inc. (“Portillo’s” or the “Company”) (NASDAQ: PTLO), the fast-casual restaurant concept known for its menu of Chicago-style favorites, today reported financial results for the second quarter ended June 30, 2024. Michael Osanloo, President and Chief Executive Officer of Portillo’s, said, “We delivered sequential improvement in both revenue and margin this quarter as we continued to prioritize sales and transaction growth. We are confident that our strategic plan is focused on the right factors, allowing us to navigate near-term challenges and seize opportunities for continuous improvement. We’re now on track to open at least 10 restaurants in 2024, including three full-service locations with an optimized footprint. We continue to successfully lower our build costs as we...

— Closed $12.5 million private placement financing led by SR One with participation from ADAR1 Capital Management and another life sciences-focused investor – — Cash resources of $54.2 million as of June 30, 2024, together with anticipated funding remaining from CIRM award, expected to fund operations into 4Q 2025 – — Topline data from Phase 2b CHASE trial of KPI-012 for PCED targeted in Q1 2025 — ARLINGTON, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) — KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today reported financial results for the second quarter ended June 30, 2024 and provided a corporate update. “Following the completion of a $12.5 million private...

On track to report preliminary data from six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC in Q4 2024 Expect to dose first patient in pivotal trial for IV Choline Chloride in Q1 2025 Current cash resources are approximately $90 million, including net proceeds from April 2024 private placement, expected to fund operations into 2026 NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) — Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today provided a business update and announced financial results for the second quarter ended June 30, 2024. “The first half of the year has been marked by significant progress as we advance our mission to deliver transformative therapies to patients with cancer and rare diseases,” said Jesse...

Enhances Focus on Returning Capital to Shareholders With Updated Dividend Policy Declares Cash Dividend of $0.25 Per Share reflecting strong financial results Highlights           (in million USD, except EPS)   Q2 2024 Q2 2023 6M 2024 6M 2023 Net Revenues   $43.1 $28.3 $81.4 $46.4   Net income / (loss)   $14.1 $0.7 $24.3 ($3.5)   Adjusted net income 1   $16.0 $3.3 $27.6 $2.9   EBITDA1   $25.8 $12.7 $47.4 $20.9   Adjusted EBITDA1   $28.0 $15.7 $51.2 $19.6               Earnings / (loss) per share Basic   $0.68 $0.03 $1.18 ($0.20)   Earnings / (loss) per share Diluted   $0.68 $0.03 $1.18 ($0.20)   Adjusted earnings per share Basic1   $0.78 $0.18 $1.35 $0.16   Adjusted earnings per share Diluted1   $0.77 $0.18 $1.34 $0.16   Other Highlights and Developments: Record second quarter net income of $14.1 million Updated...

COLUMBUS, Ohio, Aug. 06, 2024 (GLOBE NEWSWIRE) — Core Molding Technologies, Inc. (NYSE American: CMT) (“Core Molding”, “Core” or the “Company”), a leading engineered materials company specializing in molded structural products, principally in building products, industrial and utilities, medium and heavy-duty truck and powersports industries across the United States, Canada and Mexico today reports financial and operating results for the fiscal periods ended June 30, 2024. Second Quarter 2024 Highlights Total net sales of $88.7 million decreased 9.2% compared to the prior year second quarter. Gross margin of $17.7 million, or 20.0% of net sales, compared to 21.0% of net sales in the prior year second quarter. Selling, general, and administrative expenses of $10.2 million, or 11.5% of net sales, compared to $10.5 million, or 10.7%...